HORSHAM, Pa.--(BUSINESS WIRE)--Nucleonics, Inc., a biotechnology company focused on the development of novel expressed RNA interference-based (eiRNA) therapeutics, announced today that the U.S. Patent and Trademark Office has issued a fourth rejection of all of the claims of Benitec’s U.S. Patent No. 6,573,099, which is the subject of litigation Benitec brought against Nucleonics in March 2004.
